Helping Ensure Day 1 Readiness for Launch of Innovative Anti-Psychotic Therapy

An emerging life science manufacturer was planning to launch a novel, oral based therapy, targeting a population of 2.4 million patients in the highly-genericized and competitive CNS/anti-psychotic market. To bring its therapy to market, they would need to contract with both Medicaid and Medicare programs as well as enter into complex contracts with wholesalers and group purchasing organizations (GPOs).

Learn how IntegriChain helped.

Download now!

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article